{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:58:33Z","timestamp":1785859113296,"version":"3.56.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.canlet.2024.217305","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T05:55:20Z","timestamp":1729144520000},"page":"217305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["CD94 deficiency or blockade unleashes the anti-tumor immunity in mice and humanized murine models"],"prefix":"10.1016","volume":"605","author":[{"given":"Jiarui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoshuai","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7506-8806","authenticated-orcid":false,"given":"Haoyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2024.217305_bib1","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/intimm\/dxm057","article-title":"PD-1 and PD-1 ligands: from discovery to clinical application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int. Immunol."},{"key":"10.1016\/j.canlet.2024.217305_bib2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2024.217305_bib3","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.217305_bib4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.217305_bib5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.217305_bib6","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.4392.4392","article-title":"PD-1 blockade with pembrolizumab in relapsed CLL including richter's transformation: an updated report from a phase 2 trial (MC1485)","volume":"128","author":"Ding","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.217305_bib7","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2015-4059","article-title":"Crosstalk between CD8+ T and NK cells: fine-tuning of antitumor immune response","volume":"75","author":"Uzhachenko","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.217305_bib8","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","article-title":"Natural killer cell therapies","volume":"626","author":"Vivier","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.217305_bib9","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41423-019-0206-4","article-title":"Human NK cells: surface receptors, inhibitory checkpoints, and translational applications","volume":"16","author":"Sivori","year":"2019","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.canlet.2024.217305_bib10","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","article-title":"Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells","volume":"175","author":"Andre","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2024.217305_bib11","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ccell.2023.01.001","article-title":"Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.217305_bib12","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.cell.2018.10.028","article-title":"NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines","volume":"175","author":"van Montfoort","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2024.217305_bib13","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1084\/jem.185.4.795","article-title":"NKG2A complexed with CD94 defines a novel inhibitory natural killer cell receptor","volume":"185","author":"Brooks","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2024.217305_bib14","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/(SICI)1521-4141(199801)28:01<264::AID-IMMU264>3.0.CO;2-O","article-title":"Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A:: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases (vol 28, pg 264, 1998)","volume":"28","author":"Le Dr\u00e9an","year":"1998","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.canlet.2024.217305_bib15","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1074-7613(00)80574-9","article-title":"Association of DAP12 with activating CD94\/NKG2C NK cell receptors","volume":"8","author":"Lanier","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2024.217305_bib16","doi-asserted-by":"crossref","first-page":"6365","DOI":"10.4049\/jimmunol.1102345","article-title":"Rat and mouse CD94 associate directly with the activating transmembrane adaptor proteins DAP12 and DAP10 and activate NK cell cytotoxicity","volume":"187","author":"Saether","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2024.217305_bib17","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/35869","article-title":"HLA-E binds to natural killer cell receptors CD94\/NKG2A, B and C","volume":"391","author":"Braud","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.217305_bib18","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1084\/jem.190.12.1801","article-title":"Recognition of the class Ib molecule Qa-1 by putative activating receptors CD94\/NKG2C and CD94\/NKG2E on mouse natural killer cells","volume":"190","author":"Vance","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2024.217305_bib19","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1084\/jem.192.5.613","article-title":"Analysis of Qa-1 peptide binding specificity and the capacity of CD94\/NKG2A to discriminate between Qa-1-peptide complexes","volume":"192","author":"Kraft","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2024.217305_bib20","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.4049\/jimmunol.158.5.2183","article-title":"Dominance of a single peptide bound to the class I-B molecule, Qa-1(b)","volume":"158","author":"DeCloux","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2024.217305_bib21","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.18632\/oncotarget.6506","article-title":"The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma","volume":"7","author":"Yazdi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2024.217305_bib22","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/s41379-019-0322-9","article-title":"The inhibitory receptor CD94\/NKG2A on CD8(+) tumor-infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the context of HLAE\/beta2m overexpression","volume":"33","author":"Eugene","year":"2020","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.canlet.2024.217305_bib23","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1073\/pnas.95.3.1172","article-title":"HLA class I-specific inhibitory receptors in human T lymphocytes:: interleukin 15-induced expression of CD94\/NKG2A in superantigen- or alloantigen-activated CD8+ T cells","volume":"95","author":"Mingari","year":"1998","journal-title":"P Natl Acad Sci USA"},{"key":"10.1016\/j.canlet.2024.217305_bib24","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.4049\/jimmunol.169.3.1444","article-title":"Viral and bacterial infections induce expression of multiple NK cell receptors in responding CD8+ T cells","volume":"169","author":"McMahon","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2024.217305_bib25","first-page":"1165","article-title":"Differential regulation of human NK cell-associated gene expression following activation by IL-2, IFN-\u03b1 and PMA\/ionomycin","volume":"12","author":"Mori","year":"1998","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.canlet.2024.217305_bib26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/(SICI)1521-4141(199901)29:01<23::AID-IMMU23>3.0.CO;2-Y","article-title":"Transforming growth factor-\u03b2-induced expression of CD94\/NKG2A inhibitory receptors in human T lymphocytes","volume":"29","author":"Bertone","year":"1999","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.canlet.2024.217305_bib27","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1158\/0008-5472.CAN-04-2108","article-title":"Up-regulation of inhibitory natural killer receptors CD94\/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma","volume":"65","author":"Sheu","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.217305_bib28","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6074.CRICIMTEATIAACR18-A198","article-title":"The inhibitory checkpoint molecule NKG2A is upregulated on tumor-infiltrating NK cells and CD8 T-cells in human head and neck tumors","volume":"7","author":"Korrer","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2024.217305_bib29","first-page":"1195","article-title":"NKG2A is associated with CD94 on the cell surface of NK cells","volume":"99","author":"Coligan","year":"1997","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.canlet.2024.217305_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41421-024-00646-3","article-title":"Immune checkpoints HLA-E:CD94-NKG2A and HLA-C:KIR2DL1 complementarily shield circulating tumor cells from NK-mediated immune surveillance","volume":"10","author":"Liu","year":"2024","journal-title":"Cell Discov"},{"key":"10.1016\/j.canlet.2024.217305_bib31","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.4049\/jimmunol.0900907","article-title":"CD94 defines phenotypically and functionally distinct mouse NK cell subsets","volume":"183","author":"Yu","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2024.217305_bib32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/ni757","article-title":"CD94-NKG2A receptors regulate antiviral CD8+T cell responses","volume":"3","author":"Moser","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2024.217305_bib33","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.4049\/jimmunol.158.8.3603","article-title":"Natural killer cell cytolytic activity is inhibited by NKG2-A and activated by NKG2-C","volume":"158","author":"Houchins","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2024.217305_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl4414","article-title":"Immature natural killer cells promote progression of triple-negative breast cancer","volume":"15","author":"Thacker","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2024.217305_bib35","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.immuni.2009.09.014","article-title":"T helper 17 cells promote cytotoxic T cell activation in tumor immunity","volume":"31","author":"Martin-Orozco","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2024.217305_bib36","doi-asserted-by":"crossref","first-page":"5488","DOI":"10.1182\/blood-2008-10-187179","article-title":"Maturation of mouse NK cells is a 4-stage developmental program","volume":"113","author":"Chiossone","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.217305_bib37","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","article-title":"Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors","volume":"44","author":"Pitt","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2024.217305_bib38","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2024.217305_bib39","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1073\/pnas.95.9.5199","article-title":"HLA-E is a major ligand for the natural killer inhibitory receptor CD94\/NKG2A","volume":"95","author":"Lee","year":"1998","journal-title":"P Natl Acad Sci USA"},{"key":"10.1016\/j.canlet.2024.217305_bib40","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/ni.1943","article-title":"The structural basis for intramembrane assembly of an activating immunoreceptor complex","volume":"11","author":"Call","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2024.217305_bib41","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1471-4906(03)00064-4","article-title":"Expression of CD94-NKG2A inhibitory receptor is restricted to a subset of CD8+ T cells","volume":"24","author":"Braud","year":"2003","journal-title":"Trends Immunol."},{"key":"10.1016\/j.canlet.2024.217305_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005769","article-title":"Activated NK cells reprogram MDSCs via NKG2D-NKG2DL and IFN-gamma to modulate antitumor T-cell response after cryo-thermal therapy","volume":"10","author":"Peng","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canlet.2024.217305_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000450","article-title":"PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations","volume":"8","author":"Fabian","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canlet.2024.217305_bib44","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1158\/2326-6066.CIR-18-0572","article-title":"NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors","volume":"7","author":"Parihar","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2024.217305_bib45","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1158\/0008-5472.CAN-05-1299","article-title":"Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host","volume":"66","author":"Huang","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.217305_bib46","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1016\/j.celrep.2016.11.062","article-title":"Myeloid-derived suppressor cells are controlled by regulatory T cells via TGF-beta during murine colitis","volume":"17","author":"Lee","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2024.217305_bib47","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1172\/JCI123955","article-title":"Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells","volume":"129","author":"Kamiya","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2024.217305_bib48","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1385\/IR:29:1-3:081","article-title":"Qa-1, a nonclassical class I histocompatibility molecule with roles in innate and adaptive immunity","volume":"29","author":"Jensen","year":"2004","journal-title":"Immunol. Res."},{"key":"10.1016\/j.canlet.2024.217305_bib49","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/tan.12478","article-title":"Clinical and immunological significance of HLA-E in stem cell transplantation and cancer","volume":"84","author":"Wieten","year":"2014","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.canlet.2024.217305_bib50","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4049\/jimmunol.180.1.25","article-title":"Cutting edge:: engagement of NKG2A on CD8+ effector T Cells limits immunopathology in influenza pneumonia","volume":"180","author":"Zhou","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2024.217305_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007340","article-title":"Phase 1\/2 study of monalizumab plus durvalumab in patients with advanced solid tumors","volume":"12","author":"Patel","year":"2024","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.canlet.2024.217305_bib52","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1084\/jem.20072525","article-title":"CD94-NKG2A recognition of human leukocyte antigen (HLA)-E bound to an HLA class I leader sequence","volume":"205","author":"Petrie","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2024.217305_bib53","doi-asserted-by":"crossref","first-page":"6696","DOI":"10.1073\/pnas.0802736105","article-title":"Structural basis for NKG2A\/CD94 recognition of HLA-E","volume":"105","author":"Kaiser","year":"2008","journal-title":"P Natl Acad Sci USA"},{"key":"10.1016\/j.canlet.2024.217305_bib54","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/s41590-023-01523-z","article-title":"HLA class I signal peptide polymorphism determines the level of CD94\/NKG2-HLA-E-mediated regulation of effector cell responses","volume":"24","author":"Lin","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2024.217305_bib55","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/eji.200324432","article-title":"The inhibitory NK cell receptor CD94\/NKG2A and the activating receptor CD94\/NKG2C bind the top of HLA-E through mostly shared but partly distinct sets of HLA-E residues","volume":"34","author":"Wada","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.canlet.2024.217305_bib56","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1093\/emboj\/18.15.4250","article-title":"Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94\/NKG2-A and the activating receptor CD94\/NKG2-C to HLA-E","volume":"18","author":"Val\u00e9s-G\u00f3mez","year":"1999","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2024.217305_bib57","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jri.2005.12.008","article-title":"Expression patterns of lectin-like natural killer receptors, inhibitory CD94\/NKG2A, and activating CD94\/NKG2C on decidual CD56bright natural killer cells differ from those on peripheral CD56dim natural killer cells","volume":"70","author":"Kusumi","year":"2006","journal-title":"J. Reprod. Immunol."},{"key":"10.1016\/j.canlet.2024.217305_bib58","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.smim.2014.03.002","article-title":"The CD94\/NKG2C+ NK-cell subset on the edge of innate and adaptive immunity to human cytomegalovirus infection","volume":"26","author":"Lopez-Botet","year":"2014","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.canlet.2024.217305_bib59","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1182\/blood-2005-09-3682","article-title":"Expansion of CD94\/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts","volume":"107","author":"Guma","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.217305_bib60","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1189\/jlb.0710413","article-title":"NKG2A inhibits NKG2C effector functions of gammadelta T cells: implications in health and disease","volume":"89","author":"Angelini","year":"2011","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.canlet.2024.217305_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015184","article-title":"Development and function of CD94-deficient natural killer cells","volume":"5","author":"Orr","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2024.217305_bib62","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.immuni.2011.02.015","article-title":"CD94 is essential for NK cell-mediated resistance to a lethal viral disease","volume":"34","author":"Fang","year":"2011","journal-title":"Immunity"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524007006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524007006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T20:44:58Z","timestamp":1731271498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524007006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":62,"alternative-id":["S0304383524007006"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.217305","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD94 deficiency or blockade unleashes the anti-tumor immunity in mice and humanized murine models","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.217305","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"217305"}}